Mesoblast ( (MESO) ) has shared an announcement.
On February 24, 2025, Mesoblast Limited announced the appointment of Dr. Gregory George, its largest shareholder, to its Board of Directors. Dr. George, who founded and managed SurgCenter Development, brings significant operational experience to Mesoblast as it transitions to a commercial organization. His appointment is expected to enhance Mesoblast’s strategic and operational capabilities, supporting its goal of becoming a major global biotechnology company. This move is anticipated to strengthen Mesoblast’s industry positioning and potentially impact stakeholders positively by leveraging Dr. George’s expertise in innovative medical treatments.
More about Mesoblast
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe and life-threatening inflammatory conditions. The company’s proprietary mesenchymal lineage cell therapy technology platform is designed to release anti-inflammatory factors that modulate the immune system, significantly reducing damaging inflammation. Mesoblast’s RYONCIL® is the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease. The company is also developing additional therapies for various inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.
YTD Price Performance: -21.25%
Average Trading Volume: 476,643
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.13B
See more data about MESO stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com